Patient Research
Find a studySpecialtiesConditionsTreatmentsBy countryLearn
Sign in
Research.Patient.info

Severe aplastic anemia (SAA) research hub

1 indexed studies · 1 currently recruiting

  • recruitingPhase I and Phase II (Integrated)- First administration to humans

    A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia that is Refractory to or Relapsed on Immunosuppressive Therapy

    This study is testing a new medicine called REGN7257 for severe aplastic anaemia (SAA). It's for people whose SAA hasn't improved with other treatments. Researchers want to see if the new medicine is safe and if it helps people get better.

    France
Advertisement
Advertisement
Advertisement
Patient.info Research

Find clinical research studies and trials explained in plain English - powered by Patient.info.

About
  • About us
  • Advertise with us
  • Partnerships
  • Authors
  • Contact us
Research explained
  • What is a clinical trial?
  • Trial phases explained
  • Why volunteer?
  • Clinical research FAQ
  • All health-research articles
Legal
  • About our content
  • Report a correction
  • Accessibility statement
  • Cookie policy
  • Privacy policy
  • Terms of use
  • Editorial policy
Find a study

Search clinical research studies and trials by condition, location and eligibility.

Browse studies →Learn about trials →
Information only. Research.Patient.info surfaces public clinical-trial registry data and explains it in plain English. We are not affiliated with the MHRA, HRA, NHS, NIHR or any regulator. Inclusion of a study is not an endorsement and is not medical advice — always discuss with your own doctor before agreeing to take part. See about our content or report a correction.
© 2026 Navigate Health Ltd. All rights reserved.
Registered number: 16229589
Registered office: 128 City Road, London, United Kingdom, EC1V 2NX.
Patient is a UK registered trade mark.
Patient does not provide medical advice, diagnosis or treatment.